Evaluation of Expanding Pharmaceutical Data in the National Health Care Survey
This project evaluated current methods used in the National Health Care Survey to collect pharmaceutical data in the National Hospital Discharge Survey (NHDS). This study is the first step in examining the feasibility of including pharmaceuticals and had implications for the potential to include additional clinical data in the NHDS. During Phase I of the project, various practical issues of applying National Hospital Ambulatory Medical Care Survey (NHAMCS) methods to the NHDS were studied, and field procedures (forms, manuals, training) were developed to be used in th4e Phase II field test. Phase II consisted of a field test of procedures to collect the names of drugs administered to inpatients and to evaluate the use of NHAMCS methods as applied to the NHDS. Results of the study support the use of a NHAMCS type method to collect pharmaceutical data for inpatients in the NHDS. The study overview includes a list of next steps envisioned by NCHS.
FEDERAL CONTACT: Robert Pokras 301-458-4439 PIC ID: 7745
PERFORMER: CODA Inc., Silver Spring, MD
Formative Evaluation of Physician Practices Regarding Prostate Cancer
The purpose of this research project was to better understand physician behavior related to prostate cancer screening practices, factors affecting these practices, and the feasibility of using educational materials on this topic in clinical practice. The project explored whether and why physicians recommend prostate cancer screening to their patients, what physicians tell men about screening, why they do or do not discuss the pros and cons of screening with patients, and whether education materials regarding screening are relevant. Prostate cancer is the second leading cause of cancer deaths in men. Although screening tests and treatment exist, there is no clear evidence that treatment for prostate cancer reduced mortality. Professional and medical organizations have produced conflicting and confusing recommendations for clinicians. Many guidelines either advise no prostate cancer screening or recommend that physicians give men information on the pros and cons of screening and encourage men to decide whether or not to screen. Despite the controversy, limited survey data indicate that may clinicians continue to recommend prostate cancer screening. Battelle did not develop findings for this project. CDC will analyze the coded data and develop the findings.
FEDERAL CONTACT: Nancy Cheal, 404-639-7222 PIC ID: 7853
PERFORMER: Battelle, Seattle, WA